[go: up one dir, main page]

PE20040068A1 - Decanoato, undecanoato y dodecanoato de etonogestrel - Google Patents

Decanoato, undecanoato y dodecanoato de etonogestrel

Info

Publication number
PE20040068A1
PE20040068A1 PE2003000517A PE2003000517A PE20040068A1 PE 20040068 A1 PE20040068 A1 PE 20040068A1 PE 2003000517 A PE2003000517 A PE 2003000517A PE 2003000517 A PE2003000517 A PE 2003000517A PE 20040068 A1 PE20040068 A1 PE 20040068A1
Authority
PE
Peru
Prior art keywords
etonogestrel
dodecanoate
undecanoate
refers
progestogens
Prior art date
Application number
PE2003000517A
Other languages
English (en)
Inventor
Dirk Leysen
Der Voort Hendrikus Adrianus Antonius Van
Arij Jan Grootenhuis
Nijs Henrik De
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of PE20040068A1 publication Critical patent/PE20040068A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A NUEVOS PROGESTOGENOS DE ESTERES, TALES COMO DECANOATO DE ETONOGESTREL, UNDECANOATO DE ETONOGESTREL Y DODECANOATO DE ETONOGESTREL QUE SE APLICAN PARA LA ANTICONCEPCION, EN TERAPIA DE REEMPLAZO HORMONAL Y EN EL TRATAMIENTO O PREVENCION DE LOS DESORDENES GINECOLOGICOS. SE REFIERE TAMBIEN A UN KIT ANTICONCEPTIVO Y/O HRT QUE COMPRENDE UNA CANTIDAD ANTICONCEPTIVA Y/O TERAPEUTICAMENTE EFECTIVA DE LOS PROGESTOGENOS MENCIONADOS. SE REFIERE TAMBIEN AL USO DE LOS MISMOS PARA LA PREPARACION DE UN MEDICAMENTO PARA LA ANTICONCEPCION Y/O HRT
PE2003000517A 2002-05-30 2003-05-28 Decanoato, undecanoato y dodecanoato de etonogestrel PE20040068A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02077119 2002-05-30

Publications (1)

Publication Number Publication Date
PE20040068A1 true PE20040068A1 (es) 2004-02-18

Family

ID=29595014

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000517A PE20040068A1 (es) 2002-05-30 2003-05-28 Decanoato, undecanoato y dodecanoato de etonogestrel

Country Status (30)

Country Link
US (1) US7323454B2 (es)
EP (1) EP1513861B1 (es)
JP (1) JP4716726B2 (es)
KR (1) KR20050009723A (es)
CN (2) CN1314701C (es)
AR (1) AR040130A1 (es)
AT (1) ATE349458T1 (es)
AU (1) AU2003238081B2 (es)
BR (1) BR0311254A (es)
CA (1) CA2487722C (es)
CO (1) CO5631449A2 (es)
DE (1) DE60310714T2 (es)
DK (1) DK1513861T3 (es)
ES (1) ES2277085T3 (es)
HR (1) HRP20041101A2 (es)
IL (1) IL165087A0 (es)
IS (1) IS2421B (es)
MX (1) MXPA04011797A (es)
NO (1) NO20044898L (es)
NZ (1) NZ536619A (es)
PE (1) PE20040068A1 (es)
PL (1) PL373855A1 (es)
PT (1) PT1513861E (es)
RS (1) RS97604A (es)
RU (1) RU2325910C2 (es)
SI (1) SI1513861T1 (es)
TW (1) TW200403065A (es)
UA (1) UA80126C2 (es)
WO (1) WO2003102012A2 (es)
ZA (1) ZA200410410B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters
PL1909973T3 (pl) 2005-07-15 2019-01-31 Micell Technologies, Inc. Polimerowe powłoki zawierające proszek leku o kontrolowanej morfologii
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
CA2650590C (en) 2006-04-26 2018-04-03 Micell Technologies, Inc. Coatings containing multiple drugs
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
EP2271294B1 (en) 2008-04-17 2018-03-28 Micell Technologies, Inc. Stents having bioabsorbable layers
JP2011528275A (ja) 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． 薬物送達医療デバイス
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US20100239635A1 (en) 2009-03-23 2010-09-23 Micell Technologies, Inc. Drug delivery medical device
US9981072B2 (en) 2009-04-01 2018-05-29 Micell Technologies, Inc. Coated stents
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
US20130172853A1 (en) 2010-07-16 2013-07-04 Micell Technologies, Inc. Drug delivery medical device
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
JP6330024B2 (ja) 2013-03-12 2018-05-23 マイセル・テクノロジーズ，インコーポレイテッド 生体吸収性バイオメディカルインプラント
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
RU2595818C1 (ru) * 2015-05-25 2016-08-27 Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" Способ комплексного лечения дисфункции яичников при применении гормонального контрацептива имплантата "импланона"
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB845442A (en) 1956-03-22 1960-08-24 Schering Ag Manufacture of steroid compounds
DE1013284B (de) 1956-03-22 1957-08-08 Schering Ag Verfahren zur Einfuehrung der Reste wenig reaktionsfaehiger Carbonsaeuren, insbesondere des ª‰-Cyclopentyl-propionylrestes, in die 17ª‡-staendige Oxygruppe solcher Steroide, die am Kohlenstoffatom 17 neben der Oxygruppe eine Acetylgruppe tragen
GB8313921D0 (en) * 1983-05-19 1983-06-22 World Health Org Contraceptive compositions
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) 1992-12-01 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) 1993-10-01 1995-04-18 Sanei Gen F F I Inc 水溶性ヘミセルロースを含有する製剤
WO1995017896A1 (en) * 1993-12-27 1995-07-06 Akzo Nobel N.V. Percutaneously absorbable preparation
DE19613698A1 (de) 1995-07-17 1997-01-23 Schering Ag Mittel zur transdermalen Applikation enthaltend Ester des 13-Ethyl-17ß-hydroxy-11-methylen-18,19-dinor-17alpha-pregn-4-en-20-yn-3-ons
WO1997003709A1 (de) * 1995-07-17 1997-02-06 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
DE19531936A1 (de) * 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
WO1999067270A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
PT1087986E (pt) 1998-06-19 2002-08-30 Akzo Nobel Nv Undecanoato de 7alfa-metil-19-nortestosterona com actividade androgenica
US6180682B1 (en) * 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters

Also Published As

Publication number Publication date
NO20044898L (no) 2005-02-25
CO5631449A2 (es) 2006-04-28
RS97604A (sr) 2006-10-27
US7323454B2 (en) 2008-01-29
WO2003102012A3 (en) 2004-04-22
RU2004138807A (ru) 2005-05-27
CN1692122A (zh) 2005-11-02
RU2325910C2 (ru) 2008-06-10
AU2003238081A1 (en) 2003-12-19
CN101100480A (zh) 2008-01-09
IS2421B (is) 2008-10-15
SI1513861T1 (sl) 2007-06-30
JP2005532350A (ja) 2005-10-27
ZA200410410B (en) 2006-02-22
CN1314701C (zh) 2007-05-09
NZ536619A (en) 2007-09-28
HRP20041101A2 (en) 2004-12-31
PT1513861E (pt) 2007-03-30
AU2003238081B2 (en) 2008-09-18
ES2277085T3 (es) 2007-07-01
CA2487722A1 (en) 2003-12-11
EP1513861A2 (en) 2005-03-16
UA80126C2 (en) 2007-08-27
AR040130A1 (es) 2005-03-16
US20050222113A1 (en) 2005-10-06
EP1513861B1 (en) 2006-12-27
WO2003102012A2 (en) 2003-12-11
CA2487722C (en) 2011-07-19
DE60310714T2 (de) 2007-10-11
DK1513861T3 (da) 2007-04-10
IS7528A (is) 2004-11-15
KR20050009723A (ko) 2005-01-25
BR0311254A (pt) 2005-03-15
ATE349458T1 (de) 2007-01-15
PL373855A1 (en) 2005-09-19
DE60310714D1 (de) 2007-02-08
HK1072609A1 (en) 2005-09-02
WO2003102012A9 (en) 2005-01-13
MXPA04011797A (es) 2005-03-31
JP4716726B2 (ja) 2011-07-06
IL165087A0 (en) 2005-12-18
TW200403065A (en) 2004-03-01

Similar Documents

Publication Publication Date Title
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
BR0107869A (pt) Composições farmacêuticas eletrogiradas
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
AR012304A1 (es) Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
ES2155931T3 (es) Forma de administracion de un agente activo de liberacion prolongada en banda.
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
DK1089722T3 (da) Transdermalt plaster af matrixtypen til steroidhormoner
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
BRPI0400214A8 (pt) Composições e aplicações farmacêuticas para a obtenção confiável de níveis aceitáveis de testosterona no soro
GT200500003A (es) Composicion farmaceutica apta para la compresion directa para la administracion oral de cci-779
BR0214634A (pt) Sistemas terapêuticos transdérmicos contendo hormÈnio esteróide e contendo monocaprilato de propilenoglicol
GT200600307A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
ES2180690T3 (es) Preparacion de composiciones que comprenden st1435 para aplicacion topica.
AR028986A1 (es) USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
IS6317A (is) Efni og lyf til að koma í veg fyrir endaþarms- og/eða ristilskrabbamein
AR043013A1 (es) Composicion farmaceutica destinada al tratamiento de la endometriosis
BR0006556A (pt) Composição farmacêutica para uso tópico à base de corticosteróide para tratamento de fimose
CU23414B7 (es) Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva
BR9814136A (pt) Conjunto contraceptivo, processos de fabricação do mesmo e de tratamento de sangramento, usos de anti-progestogênio, de progestogênio e de anti-progestogênio, e, de um composto.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed